About achieve life sciences - ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
ACHV At a Glance
Achieve Life Sciences, Inc.
22722 29th Drive SE
Bothell, Washington 98021
| Phone | 1-425-686-1500 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -54,648,000.00 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ACHV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 12.295 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.572 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.077 |
ACHV Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,951,714.286 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ACHV Liquidity
| Current Ratio | 4.392 |
| Quick Ratio | 4.392 |
| Cash Ratio | 4.008 |
ACHV Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -135.425 |
| Return on Equity | -257.67 |
| Return on Total Capital | -149.831 |
| Return on Invested Capital | -172.093 |
ACHV Capital Structure
| Total Debt to Total Equity | 69.50 |
| Total Debt to Total Capital | 41.003 |
| Total Debt to Total Assets | 35.545 |
| Long-Term Debt to Equity | 52.003 |
| Long-Term Debt to Total Capital | 30.68 |